Suicidal behaviour in bipolar disorder: Risk and prevention

CNS Drugs

Volumn 17, Issue 7, 2003, Pages 491-511

  Tondo, Leonardo ^a,b,d   Isacsson, Göran ^c   Baldessarini, Ross J ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CLOZAPINE; DESIPRAMINE; DIBENZEPIN; DOSULEPIN; LAMOTRIGINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NOMIFENSINE; OXCARBAZEPINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; VILOXAZINE;

BIPOLAR DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HEALTH CARE ACCESS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STRESS; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

BIPOLAR DISORDER; HUMANS; RISK ASSESSMENT; RISK FACTORS; SUICIDE;

EID: 0038281515     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317070-00003     Document Type: Review

References (193)

1. Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934-41
2. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
4. Institute of Medicine. Reducing suicide. Washington, DC: The National Academics Press, 2002: 69-75
5. Tohen M, Angst J. Epidemiology of bipolar disorder. In: Tsuang MT, Tohen M, editors. Textbook in psychiatric epidemiology. 2nd ed. New York: John Wiley & Sons, 2002: 427-44
6. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-51
7. Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59 Suppl. 1: 5-30
8. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antidepressant and antianxiety agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 447-83
9. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 485-520
10. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al., editors. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4 Suppl.): 1-50
11. Baldessarini RJ, Jamison KR, editors. Effects of medical interventions on suicidal behavior. J Clin Psychiatry 1999; 60 (2 Suppl.): 1-122
12. Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract 1998; 2: 115-9
13. Isacsson G. Suicide prevention: a medical breakthrough? Acta Psychiatr Scand 2000; 102: 113-7
14. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61 Suppl. 9: 97-104
15. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch Gen Psychiatry 2000; 57: 311-7
16. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-73
17. Robins E, Murphy GE, Wilkinson RH, et al. Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. Am J Public Health 1959; 49: 888-99
18. Cheng ATA. Mental illness and suicide. Arch Gen Psychiatry 1995; 52: 594-603
19. Tanney BL. Psychiatric diagnoses and suicidal acts. In: Maris RW, Berman AL, Silverman MM, editors. Comprehensive textbook of suicidology. New York: Guilford Press, 2000: 311-41
20. Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974; 125: 355-73
21. Isometsä ET, Henriksson MM, Aro HM, et al. Suicide in bipolar disorder in Finland. Am J Psychiatry 1994; 151: 1020-4
22. Arató M, Demeter E, Rihmer Z, et al. Retrospective psychiatric assessment of 200 suicides in Budapest. Acta Psychiatr Scand 1988; 77: 454-6
23. American Association of Suicidology (AAS). Official 1998 statistics [online]. Available from URL: http://www.suicidology.org [Accessed 2000 Oct 24]
24. World Health Organization (WHO). Most recent data available, 2001 Oct [online]. Available from URL: http://www.who.int/mental_health/Topic_Suicide/suicide_rates.html [Accessed 2001 Oct 30]
25. Mäkinen IH, Wasserman D. Suicide prevention and cultural resistance: stability in suicide ranking of European countries, 1970-88. Ital J Suicidology 1997; 7: 73-85
26. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997; 170: 205-8
27. Kay DWK, Petterson U. Manic-depressive illness. Acta Psychiatr Scand 1977; 54 Suppl. 269: 55-60
28. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11: 31-42
29. Tondo L, Baldessarini RJ. Suicide: an overview [online]. Available from URL: http://www.medscape.com/Medscape/psychiatry/ ClinicalMgmt/CM.v03/public/index-CM.v03.html [Accessed 29 April 2003]
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
31. International classification of diseases. 9th ed. Geneva: World Health Organization, 1975
32. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437-8
33. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998; 172: 35-7
34. Blair-West GW, Cantor CH, Mellsop GW, et al. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999; 55: 171-8
35. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a re-examination. Am J Psychiatry 2000; 157: 1925-32
36. O'Leary D, Paykel E, Todd C, et al. Suicide in primary affective disorders revisited: a systematic review by treatment era. J Clin Psychiatry 2001; 62: 804-11
37. Lundquist G. Prognosis and course in manic-depressive psychoses. Acta Psychiatr Scand 1945; Suppl. 35: 1-96
38. Hastings DW. Follow-up results in psychiatric illness. Am J Psychiatry 1958; 114: 1058-66
39. Perris C, D'Elia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966; 42 Suppl. 194: 172-89
40. Bratfos O, Haug JP. The course of manic-depressive psychosis. Acta Psychiatr Scand 1968; 44: 89-112
41. Carlson GA, Kotin J, Davenport YB, et al. Follow-up of 53 manic-depressive patients. Br J Psychiatry 1974; 124: 134-9
42. Noriek K. Attempted suicide and suicide in functional psychoses. Acta Psychiatr Scand 1975; 52: 81-106
43. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls. Arch Gen Psychiatry 1978; 35: 153-5
44. Morrison JR. Suicide in a psychiatric practice population. J Clin Psychiatry 1982; 43: 348-52
45. Martin RL, Cloninger R, Guze SB, et al. Mortality in a follow-up of 500 psychiatric patients. Arch Gen Psychiatry 1985; 42: 58-66
46. Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord 1986; 11: 227-34
47. Black DW, Winokur G, Nasrallah A. Effect of psychosis on suicide risk in 1593 patients with unipolar and bipolar affective disorders. Am J Psychiatry 1988; 145: 849-52
48. Dingman CW, McGlashan TH. Characteristics of patients with serious suicidal intentions who ultimately commit suicide. Hosp Community Psychiatry 1988; 39: 295-9
49. Friis S, Hauff E, Island TK, et al. The Ullevål acute ward follow-up study: a personal 7-year follow-up of patients with functional psychosis admitted to the acute ward of a catchment area. Psychopathology 1991; 24: 316-27
50. Newman S, Bland R. Suicide risk varies by subtype of affective disorder. Acta Psychiatr Scand 1991; 83: 420-6
51. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91-6
52. Koukopoulos A, Reginaldi D, Minnai G, et al. The long-term prophylaxis of affective disorders. In: Gessa G, Fratta W, Pani L, editors. Depression and mania: from neurobiology to treatment. New York: Raven Press, 1995: 127-47
53. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103-7
54. Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract 1998; 2: 115-9
55. Bocchetta A, Ardau R, Burrai C, et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998; 18: 384-9
56. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59: 405-14
57. Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 419-33
58. Høyer E, Mortensen P, Olesen A. Mortality and causes of death in a total national sample of patients with affective disorders admitted for the first time between 1973 and 1993. Br J Psychiatry 2000; 176: 76-82
59. Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000; 33: 8-13
60. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42: 2-10
61. Gladstone LG, Mitchell PB, Parker G, et al. Indicators of suicide over 10 years in a specialist mood disorder unit sample. J Clin Psychiatry 2001; 62: 945-51
62. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-50
63. Lester D. Suicidal behavior in bipolar and unipolar affective disorders: a meta-analysis. J Affect Disord 1993; 27: 117-21
64. Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999; 22: 667-73
65. Bottlender R, Jager M, Strauss A, et al. Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 2000; 250: 257-61
66. Ahrens B, Müller-Oerlinghausen B, Schou M, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 67-75
67. Móscicki EK. Epidemiology of completed and attempted suicide: toward a framework for prevention. Clin Neurosci Res 2001; 1: 310-23
68. Dilsaver SC, Chen Y-W, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure mania. Psychiatry Res 1997; 73: 47-56
69. Hirschfeld RMA, Davidson L. Clinical risk factors for suicide. Psychiatr Ann 1988; 18: 628-35
70. Jacobs DG, Brewer M, Klein-Benheim M. Suicide assessment: an overview and recommended protocol. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 3-39
71. Sachs GS, Yan LJ, Swann AC, et al. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry 2001; 62 Suppl. 25: 3-11
72. Frances RJ, Franklin J, Flavin DK. Suicide and alcoholism. Am J Drug Alcohol Abuse 1987; 13: 327-41
73. Móscicki EK. Identification of suicide risk factors using epidemiologic studies. Psychiatr Clin North Am 1997; 20: 499-517
74. Strakowski SM, Del Bello MP, Flex DE, et al. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 48: 477-85
75. Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 63-9
76. Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry 2001; 62 Suppl. 25: 27-30
77. Fawcett J. Suicide assessment: an overview and recommended protocol. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 115-24
78. Mann JJ, Waternaux C, Haas GL, et al. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156: 181-9
79. Corruble E, Damy C, Guelfi JD. Impulsivity: a relevant dimension in depression regarding suicide attempts? J Affect Disord 1999; 53: 211-5
80. Goldberg JF, Singer TM, Garno JL. Suicidality and substance abuse in affective disorders. J Clin Psychiatry 2001; 62 Suppl. 25: 35-43
81. Baca-García E, Diaz-Sastre C, Basurte E, et al. A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. J Clin Psychiatry 2001; 62: 560-4
82. Wu LH, Dunner DL. Suicide attempts in rapid cycling bipolar disorder patients. J Affect Disord 1993; 29: 57-61
83. Goodwin FK. Anticonvulsant therapy and suicide in affective disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 89-93
84. Wender PH, Kety SS, Rosenthal D, et al. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 1986; 43: 923-9
85. Turecki G. Suicidal behavior: is there a genetic predisposition? Bipolar Disord 2001; 3: 335-49
86. Conwell Y, Henderson RE. Neuropsychiatry of suicide. In: Fogel BS, Schiffer RB, Rao SM, editors. Neuropsychiatry. Baltimore (MD): Williams & Wilkins, 1996: 485-521
87. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res 1967; 11: 213-8
88. Rich CL, Warsradt GM, Nemiroff RA, et al. Suicide, stressors, and the life cycle. Am J Psychiatry 1991; 148: 524-6
89. Minois G. History of suicide: voluntary death, in western culture. Baltimore (MD): Johns Hopkins University Press, 1999
90. Tondo L. Prima del tempo. Rome: Carocci, 2000
91. Shneidman ES. Suicide, lethality, and the psychological autopsy. Int Psychiatry Clin 1969; 6: 225-50
92. Beck AT, Beck R, Kovacs M. Classification of suicidal behaviors: quantifying intent and medical lethality. Am J Psychiatry 1975; 132: 285-7
93. Rich CL, Young JG, Fowler RC, et al. Guns and suicide: possible effects of some specific legislation. Am J Psychiatry 1990; 147: 342-6
94. Rich CL, Dhossche DM, Ghani S, et al. Suicide methods and presence of intoxicating abusable substances: some clinical and public health implications. Ann Clin Psychiatry 1998; 10: 169-75
95. Perlis RH, Stern TA. Suicide. In: Stern TA, Herman JB, editors. Psychiatry update and board preparation. New York: McGraw-Hill, 2000: 409-13
96. Hirschfeld RMA, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997; 337: 910-5
97. Leenaars AA. Suicide notes: predictive clues and patterns. New York: Human Sciences Press, 1988
98. Pirkis J, Burgess P. Suicide and recency of health care contacts: a systematic review. Br J Psychiatry 1998; 173: 462-74
99. Miller CL, Druss B. Suicide and access to care. Psychiatr Serv 2001; 52: 1566-7
100. Andersen UA, Andersen M, Rosholm JU, et al. Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatr Scand 2000; 102: 126-34
101. Franks P, Clancy CM, Marthe R. Health insurance and mortality: evidence from a national cohort. JAMA 1993; 270: 737-41
102. Baker DW, Sudano JJ, Albert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Engl J Med 2001; 345: 1106-12
103. US Census Bureau. Statistical abstract of the United States. Washington, DC: US Government Printing Office, 2000
104. Center for Disease Control. Health statistics for the US. Atlanta (GA): US National Center for Health Statistics, 2001
105. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986; 43: 458-66
106. Isacsson G, Holmgren P, Wasserman D, et al. Use of antidepressants among people committing suicide in Sweden. BMJ 1994; 308: 506-9
107. Isacsson G, Bergman U, Rich CL. Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Disord 1994; 32: 277-86
108. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333-40
109. Isacsson G, Holmgren P, Druid H, et al. Psychotropics and suicide prevention: implications from toxicological screening of 5281 suicides in Sweden, 1992-1994. Br J Psychiatry 1999; 174: 259-65
110. Andersen UA, Andersen M, Rosholm JU, et al. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 2001; 104: 458-65
111. Baldessarini RJ, Tondo L, Hennen J. Reduced suicide risk during long-term treatment with lithium. Ann N Y Acad Sci 2001; 932: 24-43
112. Malone KM. Pharmacotherapy of affectively ill suicidal patients. Psychiatr Clin North Am 1997; 20: 613-25
113. Salzman C. Treatment of the suicidal patient with psychotropic drugs and ECT. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 372-82
114. Müller-Oerlinghausen B, Berghofer A. Antidepressants and suicidal risk. J Clin Psychiatry 1999; 60 Suppl. 2: 94-9
115. Carlsten A, Waern M, Ekedahl A, et al. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10: 525-30
116. Joyce PR. Improvements in the recognition and treatment of depression and decreasing suicide rates. N Z Med J 2001; 114: 535-6
117. Isacsson G, Holmgren P, Druid H, et al. The utilization of antidepressants: a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden 1992-94. Acta Psychiatr Scand 1997; 96: 94-100
118. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987; 295: 1021-4
119. Ohberg A, Vuori E, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord 1998; 50: 225-33
120. Frey R, Schreinzer D, Stimpfl T, et al. Suicide by antidepressant intoxication identified at autopsy in Vienna, 1991-1997: the favorable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 2000; 10: 133-42
121. Isacsson G, Boëthius G, Henriksson S, et al. Selective serotonin reuptake inhibitors have broadened the utilization of antidepressant treatment in accordance with recommendations: findings from a Swedish prescription database. J Affect Disord 1999; 53: 15-22
122. Isacsson G. Frequency of suicides reduced with 25 percent: probably by the increased use of antidepressive agents. Lakartidningen 2000; 97: 1644-50
123. Rihmer Z, Belso N, Kalmár S. Antidepressants and suicide prevention in Hungary. Acta Psychiatr Scand 2001; 103: 238-9
124. Murphy GE. Why women are less likely than men to commit suicide. Compr Psychiatry 1998; 39: 165-75
125. Monk M. Epidemiology of suicide. Epidemiol Rev 1987; 9: 51-69
126. Klerman GL, Weissman MM. Increasing rate of depression. JAMA 1989; 261: 2229-35
127. Clark DC, Goebel-Fabbri AE. Lifetime risk of suicide in major affective disorders. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 270-86
128. Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685-92
129. Isacsson G, Redfors I, Wasserman D, et al. Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden. BMJ 1994; 309: 1546-9
130. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215-8
131. Barbui C, Campomori A, D'Avanzo B, et al. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999; 34: 152-6
132. Leon AC, Keller MB, Warshaw MG, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999; 156: 195-201
133. Matthews JD, Fava M. Risk of suicidality in depression with serotonergic antidepressants. Ann Clin Psychiatry 2000; 12: 43-50
134. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027-33
135. Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1992; 52: 491-2
136. Tollefson GD, Rampey AH, Beasley CM, et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163-9
137. Healy D, Langmaak C, Savage M. Suicide in the course of the treatment of depression. J Psychopharmacol 1999; 13: 94-9
138. Åsberg M. Neurotransmitters and suicidal behavior: evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997; 836: 158-81
139. Roy A, Nielsen D, Rylander G, et al. Genetics of suicide in depression. J Clin Psychiatry 1999; 60 Suppl. 2: 12-7
140. van Praag HM. Serotonin disturbances and suicide risk: is aggression or anxiety the interjacent link? Crisis 2000; 21: 160-2
141. Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729-38
142. Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001; 24: 467-77
143. Jamison KR. Suicide and bipolar disorders. Ann N Y Acad Sci 1986; 487: 301-15
144. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261-70
145. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60: 77-84
146. Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-72
147. Coppen A, Standish-Barry H, Bailey J, et al. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7
148. Modestin J, Schwarzenbach F. Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatr Scand 1992; 85: 173-5
149. Nilsson A. Lithium therapy and suicide risk. J Clin Psychiatry 1999; 60 Suppl. 2: 85-8
150. Schou M. Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1999; 1: 5-10
151. Oquendo MA, Barrera A, Mann JJ. Psychopharmacological strategies for the prevention of suicidal behavior in bipolar patients. Clin Neurosci Res 2001; 1: 387-93
152. Tondo L, Ghiani C, Albert M. Pharmacologic interventions in suicide prevention. J Clin Psychiatry 2001; 62 Suppl. 25: 51-5
153. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993; 50: 448-55
154. Baldessarini RJ, Tondo L, Viguera AC. Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999; 1: 17-24
155. Norton B, Whalley LJ. Mortality of a lithium-treated population. Br J Psychiatry 1984; 145: 277-82
156. Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991; 21: 33-8
157. Müller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl. 2: 72-5
158. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132-6
159. Young LT, Warsh JJ, Kish SJ, et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35: 121-7
160. Wickham EA, Reed FV. Lithium for the control of aggressive and self-mutilating behavior. Int Clin Psychopharmacol 1977; 2: 181-90
161. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60: 82-91
162. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14: 277-81
163. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997; 43: 151-61
164. Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta-analysis. Br J Psychiatry 1995; 166: 378-81
165. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-8
166. Goodwin FK, Fireman B, Simeon G, et al. Suicide attempts in bipolar patients on lithium vs divalproex. The 41st Annual Meeting of The American College of Neuropsychopharmacology; 2002 Dec 8-12; San Juan, Puerto Rico
167. Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia: focus on the role of clozapine. CNS Drugs 2000; 14: 355-65
168. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-9
169. Sernyak MJ, Desai R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931-7
170. Ciapparelli A, Dell'Osso L, Pini S, et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329-34
171. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62-9
172. Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry. 2002; 63 Suppl. 3: 10-4
173. Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord 1999; 1: 123-4
174. Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998; 59 Suppl. 12: 41-5
175. Avery D, Winokur G. Suicide, attempted suicide, and relapse rates in depression. Arch Gen Psychiatry 1978; 35: 749-53
176. Metzger ED. ECT and suicide. In: Jacobs DG, editor. Harvard Medical School guide to assessment and intervention in suicide. San Francisco (CA): Jossey-Bass, 1998: 406-14
177. Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. J Clin Psychiatry 1999; 60 Suppl. 2: 104-10
178. Ciapparelli A, Dell'Osso L, Tundo A, et al. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J Clin Psychiatry 2000; 62: 552-5
179. Sharma V. The effect of electroconvulsive therapy on suicide risk in patients with mood disorders. Can J Psychiatry 2001; 46: 704-9
180. Weinger RD, editor. American Psychiatric Association Task Force on Electroconvulsive Therapy: the practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: APA Press, 2000
181. Rose RM, Burt RA, Clayton PJ. Consensus development conference statement: electroconvulsive therapy. JAMA 1985; 254: 2103-8
182. Grandin LD, Yan LJ, Gray SM, et al. Suicide prevention: increasing education and awareness. J Clin Psychiatry 2001; 62 Suppl. 25: 12-6
183. Pearson JL, Stanley B, King CA, et al. Intervention research with persons at high risk for suicidality: safety and ethical considerations. J Clin Psychiatry 2001; 62 Suppl. 25: 17-26
184. Gray SM, Otto MW. Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. J Clin Psychiatry 2001; 62 Suppl. 25: 56-64
185. Taylor SJ, Kingdom D, Jenkins R. How are nations trying to prevent suicide? An analysis of national prevention strategies. Acta Psychiatr Scand 1997; 95: 45-63
186. Welu TC. A follow-up program for suicide attempters: evaluation of effectiveness. Suicide Life Threat Behav 1977; 7: 17-30
187. Swahn MH, Potter LBS. Factors associated with the medical severity of suicide attempts in youths and young adults. Suicide Life Threat Behav 2001; 32 (1 Suppl.): 21-9
188. Hawton K, McKeown S, Day A, et al. Evaluation of outpatient counseling compared with general practitioner care following overdoses. Psychol Med 1987; 17: 751-61
189. Salkovskis PM, Atha C, Storer D. Cognitive-behavioral problem solving in the treatment of patients who repeatedly attempt suicide: a controlled trial. Br J Psychiatry 1990; 157: 871-6
190. Linehan MM, Heidi HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal border-line patients. Arch Gen Psychiatry 1993; 50: 971-4
191. McLeavey BC, Daly RJ, Ludgate JW, et al. Interpersonal problem-solving skills training in the treatment of self-poisoning patients. Suicide Life Threat Behav 1994; 24: 382-94
192. Egan MP. Contracting for safety: a concept analysis. Crisis 1997; 18: 17-23
193. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000; 8: 126-40